Hybio Pharmaceutical Co.Ltd(300199) ( Hybio Pharmaceutical Co.Ltd(300199) ) said on the interactive platform today that the action mechanism of the polypeptide nasal spray developed by the company is different from that of Pfizer’s recently listed oral tablets. At present, it is still in the stage of rapid development. From the public data of efficacy in vitro, the inhibitory activity of the polypeptide nasal spray developed by the company is about 60 times higher than that of Pfizer.
© China Stock Market News